| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/07/2002 | US6384222 N-benzenesulfonyl-L-proline compounds, preparation method and method for using the compounds in therapy |
| 05/07/2002 | US6384220 Antidiabetic agents increasing the expression of glucokinase (gk) to improve glucose tolerance; increase in glucose exposure coupled through gk in beta-cells to increase insulin secretion and in hepatocytes to increase glycogen deposition |
| 05/07/2002 | US6384213 Process for preparing a pure, pharmacopoeial grade amorphous form of cefuroxime axetil |
| 05/07/2002 | US6384202 Cell-specific active compounds regulated by the cell cycle |
| 05/07/2002 | US6384195 Produced by partitioning method; therapeutics |
| 05/07/2002 | US6384193 Agents for the regulation of oestrogen synthesis |
| 05/07/2002 | US6384186 Cyclic dodecapeptide and process for the preparation thereof |
| 05/07/2002 | US6384088 Comprehensive pharmacologic therapy for treatment of obesity |
| 05/07/2002 | US6384087 Materials and methods for the treatment or prevention of obesity |
| 05/07/2002 | US6384086 Administering to host effective amount of storage stable ethene for improving metabolic function |
| 05/07/2002 | US6384085 Antioxidative ingredients extracted from powdered ecklonia cava one or more times with organic solvent, fractionated one or more times in solvents, and purified by chromatography |
| 05/07/2002 | US6384084 Histochrome and its therapeutic use in ophthalmology |
| 05/07/2002 | US6384083 Controlling viruses of bornaviridae family by administering adamantane amines to human and animals at therapeutically effective dosage by means selected from oral, parenteral, intramuscular, subcutaneous, intradermal and topical |
| 05/07/2002 | US6384081 Treatment of diseases of the eye characterized by the formation of metalloproteinase |
| 05/07/2002 | US6384080 Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase |
| 05/07/2002 | US6384079 Topically effective, skin-treating composition prepared by combining nystatin and/or hormone and enhancing amount of member selected from hydroxycarboxylic acids, lactones or salts and related ketocarboxylic acids, esters or salts |
| 05/07/2002 | US6384078 Method of treating elevated cholesterol levels by enhancing the effectiveness of the human immune system |
| 05/07/2002 | US6384077 Highly purified EPA for treatment of schizophrenia and related disorders |
| 05/07/2002 | US6384075 Treating diseases in which mast cell dysfunction is involved |
| 05/07/2002 | US6384074 Activating cell growth in human by applying specified plant extract to skin |
| 05/07/2002 | US6384073 Use of macrolide compounds for treating glaucoma |
| 05/07/2002 | US6384072 Carbamyl substituted compounds with ether groups |
| 05/07/2002 | US6384070 Restenosis, kidney diseases, lung diseases |
| 05/07/2002 | US6384069 Brain disorders chronic pain, hypoglycemia, hypoxia, trauma, alzheimer's disease, aids-associated dementia, amyotrophic lateral sclerosis, parkinson's disease, and chronic alcoholism, comprising administering to a patient in need a |
| 05/07/2002 | US6384064 Human immunodeficiency syndrone, hepatitis virus |
| 05/07/2002 | US6384063 Compound having effect of promoting neuron differentiation |
| 05/07/2002 | US6384062 Pharmaceutical composition |
| 05/07/2002 | US6384059 Crystalline form of omeprazole |
| 05/07/2002 | US6384056 Cognition activators and nerve and vision disorders |
| 05/07/2002 | US6384055 Analgesics |
| 05/07/2002 | US6384054 Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients |
| 05/07/2002 | US6384052 Anticoccidial compounds |
| 05/07/2002 | US6384051 Antitumor agents |
| 05/07/2002 | US6384049 Cancer treatment |
| 05/07/2002 | US6384048 Imidazonaphthyridines |
| 05/07/2002 | US6384047 Breathing disorders and hypotensive agents |
| 05/07/2002 | US6384046 Treating neointimal proliferation and thickening |
| 05/07/2002 | US6384044 Method of treating cancer of the prostate |
| 05/07/2002 | US6384043 Applying analgesic to eye for pain relief |
| 05/07/2002 | US6384042 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 05/07/2002 | US6384041 Bicyclic sPLA2 inhibitors |
| 05/07/2002 | US6384039 QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death |
| 05/07/2002 | US6384038 Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| 05/07/2002 | US6384037 R-hydroxynefazodone |
| 05/07/2002 | US6384036 Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
| 05/07/2002 | US6384035 Heterocycles useful in the treatment of benign prostatic hyperplasia |
| 05/07/2002 | US6384034 Method of treating migraines and pharmaceutical compositions |
| 05/07/2002 | US6384030 Water soluble azoles as broad-spectrum antifungals |
| 05/07/2002 | US6384029 Optically active pyridyl-4h-1,2,4-oxdadiazine derivative and its use in the treatment of vascular diseases |
| 05/07/2002 | US6384028 Treatment of cardiovascular disorders, anticoagulants and valve replacement |
| 05/07/2002 | US6384027 Phthalocyanine analogs |
| 05/07/2002 | US6384025 Skin disorders; reacting retinol with chloroformate compound |
| 05/07/2002 | US6384024 Bile salt conjugates |
| 05/07/2002 | US6384023 Silicone gel containing salicylic acid |
| 05/07/2002 | US6384022 Enzyme inhibitors |
| 05/07/2002 | US6384021 Heparin compositions of very low molecular weight |
| 05/07/2002 | US6384020 Rapid immediate release oral dosage form |
| 05/07/2002 | US6384019 Gemcitabine derivatives |
| 05/07/2002 | US6383808 Antisense inhibition of clusterin expression |
| 05/07/2002 | US6383799 Culturing tremella mesenterica in submerged culture on nutrient media, then isolating biomass by alcohol precipitation |
| 05/07/2002 | US6383793 Human osteoclast-derived cathepsin |
| 05/07/2002 | US6383790 Pyrazolo(3,4-d)pyrimidine based compound; anticarcinogenic agents; antitumor agents |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383764 Administering peptide or functional peptide analog to mammal and determining ability of compound to control seizures |
| 05/07/2002 | US6383733 Methods of screening for pharmacologically active compounds for the treatment of tumour diseases |
| 05/07/2002 | US6383529 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 05/07/2002 | US6383528 Antithrombotic preparation to suppress neutropenia, agranulocytosis, ischemia, and other side effects from the use of ticlopidine alone; |
| 05/07/2002 | US6383524 Compositions and methods for enhancing therapeutic effects |
| 05/07/2002 | US6383521 Sponge extract (wondonin a) with antiangiogenesis and anticarcinogenic properties; non-cytotoxic |
| 05/07/2002 | US6383520 Fine powder of L-α-aminoadipic acid derivative, oral solid preparations containing the same, and method for treatment of bulk powders |
| 05/07/2002 | US6383516 Sustained-release microgranules containing diltiazem as active principle |
| 05/07/2002 | US6383514 Hypocholesterolemic composition comprising a phytostanol ester and a tocopherol |
| 05/07/2002 | US6383513 Compositions comprising cannabinoids |
| 05/07/2002 | US6383512 For delivering to cell a composition comprising local anesthetic and nucleic acid molecules that comprise a nucleotide sequence that encodes an antisense oligonucleotide, a ribozyme, and a triplex forming nucleic acid |
| 05/07/2002 | US6383511 Local prevention or amelioration of pain from surgically closed wounds |
| 05/07/2002 | US6383510 Suppository form comprising an acid-labile active compound |
| 05/07/2002 | US6383509 Continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years; neurotoxin, especially botulinum toxin or clostridial neurotoxin, within a polymeric matrix |
| 05/07/2002 | US6383505 Fast-acting antimicrobial lotion with enhanced efficacy |
| 05/07/2002 | US6383500 Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| 05/07/2002 | US6383499 Topical medicament for the treatment of psoriasis |
| 05/07/2002 | US6383490 Drug abuse or dependance |
| 05/07/2002 | US6383486 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 05/07/2002 | US6383482 Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus |
| 05/07/2002 | US6383474 Carotenoid preparation |
| 05/07/2002 | US6383069 Methods and apparatus for performing processing operations on a slaughtered animal or part thereof |
| 05/07/2002 | CA2361071A1 Combination therapies for the stimulation of bone growth |
| 05/07/2002 | CA2348845A1 Adenosine as antithrombotic |
| 05/07/2002 | CA2229746C Orthomolecular medical use of l-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
| 05/07/2002 | CA2216535C Protein kinase c inhibitors |
| 05/07/2002 | CA2215038C Process for the preparation of pharmaceutically acceptable salts of clavulanic acid |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/07/2002 | CA2214503C Method for treating tumors |
| 05/07/2002 | CA2205305C Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams |
| 05/07/2002 | CA2175842C Transesterified corn oil products |
| 05/07/2002 | CA2145000C Compounds which are selective antagonists of the human nk3 receptor and their use as medicinal products and diagnostic tools |
| 05/07/2002 | CA2108782C Composition and method for treatment of patulous eustachian tube syndrome and atrophic rhinitis |
| 05/07/2002 | CA2088760C Use of 2-phenyl-1,2-benzisoselanazol-3-(2h)-one |
| 05/07/2002 | CA2085871C A controlled release drug dispersion delivery device |
| 05/06/2002 | WO2002038178A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer |